Allied (Allied) Current Accrued Expense : $0.00 Mil (As of Feb. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Allied Current Accrued Expense?

Allied's Current Accrued Expense for the quarter that ended in Feb. 2024 was $0.00 Mil.

Allied Current Accrued Expense Historical Data

The historical data trend for Allied's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allied Current Accrued Expense Chart

Allied Annual Data

Trend

Mar18

Mar19

Aug20

Aug21

Aug22

Aug23

Current Accrued Expense

Get a 7-Day Free Trial

1.40

Allied Quarterly Data
	Mar19	Jun19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Current Accrued Expense	Get a 7-Day Free Trial															-	-	-	-	-

Allied Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Allied Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Allied's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Allied (Allied) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Allied Corp (OTCPK:ALID) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1405 St. Paul Street, Suite 201, Kelowna, BC, CAN, V1Y 9N2

Website

https://www.allied.health

Allied Corp is an international cannabis company with a mission to help people suffering from Post-Traumatic Stress Disorder (PTSD) by researching, creating, and producing targeted cannabinoid health solutions. The company uses an evidence-informed scientific approach to make this mission possible through cutting-edge pharmaceutical research and development, plant-based production, and the development of therapeutic products. The company operates in two segments which include Allied and Allied Colombia. Its geographical segments consist of Colombia and Canada. The company's revenue is comprised ofsales ofcannabis products.

Executives

James George Robinson	director, 10 percent owner	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Anthony Zelen	director, 10 percent owner	1406 MINE HILL LANE, KELOWNA A1 V1P 1S5
Calum Hughes	director, 10 percent owner, officer: Chief Executive Officer	1847 CROSSGLEN COURT, KELOWNA A1 V1V 1S4
David Weinkauf	director, 10 percent owner, officer: Chief Business Development Off	192 SIERRA MORENA LANDING, SW CALGARY A0 T3H 4K4
Paul James Bullock	director, 10 percent owner, officer: Chief Operating Officer	1400 ST PAUL ST, SUITE 201, KELOWNA Z4 V1Y9N2